Related Experiment Video
Updated: Feb 14, 2026
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer
Seher Nazlı Kazaz1, İlhan Öztop2
1Department of Medical Oncology, Kanuni Training and Research Hospital, Trabzon, Turkey.
Abstract:
More than half of non-small cell lung cancer (NSCLC) patients are at an advanced stage at the time of diagnosis, and they have a poor prognosis. Systemic treatment is the basic treatment approach for advanced-stage NSCLC, and chemotherapy and targeted treatments are commonly used based on the molecular characteristics. Although targeted therapies have led to a significant level of improvement in terms of survival, the results are still unsatisfactory. However, considerable attention has been focused to the immunotherapy with recent positive results reported by studies on this field. In this context, a certain portion of clinical studies have shown dramatic results, and these have involved inhibitors developed particularly against the immune checkpoint protein programmed death receptor-1 and its ligand (programmed death ligand-1). This review aims to present the significance of immune checkpoint inhibitors in NSCLC and to summarize the findings of relevant contemporary clinical studies.
Insights
Immune checkpoint inhibitors targeting programmed death receptor-1 and programmed death ligand-1 show promise for advanced non-small cell lung cancer (NSCLC) patients. This review highlights their significance and summarizes recent clinical study findings in NSCLC treatment.
Area of Science:
- Oncology
- Immunology
- Medical Research
Background:
- Advanced non-small cell lung cancer (NSCLC) presents a poor prognosis, with over half of patients diagnosed at this stage.
- Current systemic treatments like chemotherapy and targeted therapies offer limited long-term survival benefits.
- Emerging immunotherapies, particularly immune checkpoint inhibitors, are showing significant promise in improving patient outcomes.
Purpose of the Study:
- To underscore the importance of immune checkpoint inhibitors in managing advanced NSCLC.
- To provide a comprehensive summary of recent clinical studies involving these novel therapies.
Main Methods:
- Review of contemporary clinical studies focusing on immune checkpoint inhibitors in NSCLC.
- Analysis of data related to inhibitors targeting programmed death receptor-1 (PD-1) and programmed death ligand-1 (PD-L1).
Main Results:
- Clinical studies have demonstrated dramatic improvements in survival for a subset of NSCLC patients treated with PD-1/PD-L1 inhibitors.
- These inhibitors represent a significant advancement over traditional therapies for advanced NSCLC.
Conclusions:
- Immune checkpoint inhibitors are a critical development in the treatment of advanced NSCLC.
- Further research and clinical application of PD-1/PD-L1 inhibitors are warranted to improve NSCLC patient prognosis.
Related Concept Videos
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:38What is the Immune System?
01:47Lung Capacity
01:40Cell-mediated Immune Responses
01:23Cells of the Adaptive Immune Response